🔥🐔 BizChicken 🐔🔥

Companies Similar to Sagimet Biosciences Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Rencofilstat

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drug therapies for chronic liver diseases, particularly through the development of Rencofilstat, a cyclophilin inhibitor aimed at treating non-alcoholic steatohepatitis (NASH) and reducing liver fibrosis and tumors.

Tags: NASH, Rencofilstat, biopharmaceutical, cyclophilin inhibitor, drug therapy, liver disease

Symbol: HEPA

Recent Price: $0.43

Industry: Biotechnology

CEO: Mr. John Patrick Brancaccio CPA

Sector: Healthcare

Employees: 22

Address: 399 Thornall Street, Edison, NJ 08837

Phone: 732 902 4000

Leadership

  • John P. Brancaccio, Interim Chief Executive Officer, Interim Chief Financial Officer, and Chairman of the Board

Last updated: 2024-12-31

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

Sotagliflozin, LX9211

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products, with drugs like Sotagliflozin and LX9211 under development for heart failure, type 1 diabetes, and neuropathic pain.

Tags: biopharmaceutical, drug development, heart failure, neuropathic pain, type 1 diabetes

Symbol: LXRX

Recent Price: $0.72

Industry: Biotechnology

CEO: Dr. Michael Exton Ph.D.

Sector: Healthcare

Employees: 285

Address: 2445 Technology Forest Boulevard, The Woodlands, TX 77381

Phone: 281 863 3000

Leadership

  • Brian Corrigan, Senior Vice President, Regulatory and Quality Assurance
  • Brian Crum, Senior Vice President and General Counsel
  • Lisa DeFrancesco, Vice President, Investor Relations and Corporate Communications
  • Mike Exton, Ph.D., Chief Executive Officer and Director
  • Tom Garner, Senior Vice President and Chief Commercial Officer
  • Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
  • Alan Main, PhD, Executive Vice President, Innovation and Chemical Sciences
  • Wendy McDermott, Senior Vice President, Human Resources
  • Kristen Alexander, Vice President, Finance and Accounting
  • Phillip Banks, MS, FRS, Vice President, Biostatistics and Data Management
  • Kyle Burt, Vice President, Information Operations
  • Amy Carroll, Ph.D., Vice President, Medical Affairs
  • Melinda Francini, Vice President, Value and Access
  • Desiree Gendron, Vice President, Sales and Training
  • Suma Gopinathan, Ph.D., Vice President, Clinical Development
  • Rachel Martens, Vice President, Partnerships and Corporate Strategy
  • Nicole Moore, Vice President, Legal
  • Tracy Newbold, Vice President, Clinical Operations
  • Godfried Owusu-Ababio, Vice President, Technical Operations
  • Rob Scala, Vice President, Business Planning and Commercial Operations
  • Carrie Siragusa, Vice President, Marketing
  • Dixon Terry, Vice President, Compliance
  • Raymond Debbane, Chairman
  • Philippe J. Amouyal,
  • Samuel L. Barker, PhD,
  • Robert J. Lefkowitz, MD,
  • Christopher J. Sobecki,
  • Diane E. Sullivan,
  • Judith L. Swain, MD,

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Abivax SA American Depositary Shares

Abivax SA American Depositary Shares logo
Market Cap: Medium
Employees: Lowest

obefazimod

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.

Tags: biotechnology, chronic inflammatory diseases, clinical trials, immune response, ulcerative colitis

Symbol: ABVX

Recent Price: $7.05

Industry: Biotechnology

CEO: Mr. Marc M. P. de Garidel M.B.A.

Sector: Healthcare

Employees: 62

Address: 7-11 boulevard Haussmann, Paris, null 75009

Phone: 33 1 53 83 09 63

Leadership

  • Marc de Garidel, MBA, Chief Executive Officer
  • Didier Blondel, EVP, Chief Financial Officer & Board Secretary
  • Fabio Cataldi, MD, Chief Medical Officer
  • Ida Hatoum, Chief People Officer, Chief Compliance Officer
  • David Zhang, PhD, Chief Strategy Officer
  • Pierre Courteille, Pharmacist, MBA, Chief Business Officer
  • Didier Scherrer, PhD, Chief Scientific Officer
  • Jérôme Denis, PhD, EVP, Process Development & Manufacturing
  • Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
  • Sylvie Grégoire, PharmD, Chair of the Board
  • Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
  • Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
  • June Lee, MD FACCP, Venture Partner at 5AM Ventures
  • Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
  • Troy Ignelzi, CFO of Rapport Therapeutics
  • Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
  • Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
  • Hema Keshava, Senior Vice President, Finance
  • Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
  • Patrick Malloy, Senior Vice President, Investor Relations
  • Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
  • Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
  • Kevin Shan, PhD, Vice President, Global Head of Biometrics
  • Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
  • Ana Sharma, MPH, Vice President, Global Head of Quality
  • Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture

Last updated: 2024-12-31

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Vadadustat

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.

Tags: CKD, anemia, biopharmaceutical, chronic kidney disease, kidney diseases, therapeutics, vadadustat

Symbol: AKBA

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. John P. Butler MBA

Sector: Healthcare

Employees: 167

Address: 245 First Street, Cambridge, MA 02142

Phone: 617 871 2098

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

Coherus BioSciences, Inc.

Coherus BioSciences, Inc. logo
Market Cap: Low
Employees: Low

UDENYCA

Coherus Bio Sciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. It markets UDENYCA and develops various biosimilar and immuno-oncology products.

Tags: Toripalimab, UDENYCA, biopharmaceutical, biosimilars, immuno-oncology

Symbol: CHRS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Dennis M. Lanfear

Sector: Healthcare

Employees: 306

Address: 333 Twin Dolphin Drive, Redwood City, CA 94065

Phone: 650 649 3530

Last updated: 2024-12-31

Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Fadraciclib, CYC140, Sapacitabine, Seliciclib

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of medicines for treating cancer and other proliferative diseases. The company's key development programs include fadraciclib, CYC140, Sapacitabine, and seliciclib, targeting various forms of cancer and other conditions.

Tags: CDK inhibitors, biopharmaceutical, cancer treatment, clinical trials, proliferative diseases

Symbol: CYCC

Recent Price: $0.37

Industry: Biotechnology

CEO: Mr. Spiro George Rombotis

Sector: Healthcare

Employees: 12

Address: 200 Connell Drive, Berkeley Heights, NJ 07922

Phone: 908 517 7330

Last updated: 2024-12-31

Fortress Biotech, Inc.

Fortress Biotech, Inc. logo
Market Cap: Lowest
Employees: Low

Pharmaceutical and Biotechnology Products

Fortress Biotech, Inc., is a biopharmaceutical company focused on developing and commercializing a range of dermatology products and late-stage product candidates for various medical conditions.

Tags: Menkes disease, NSCLC, acne treatment, amyloidosis, biopharmaceutical, biotechnology, cancer treatment, dermatology, immunodeficiency, pain management, pharmaceutical, vaccines

Symbol: FBIO

Recent Price: $2.18

Industry: Biotechnology

CEO: Dr. Lindsay Allan Rosenwald

Sector: Healthcare

Employees: 186

Address: 1111 Kane Concourse, Bay Harbor Islands, FL 33154

Phone: 781 652 4500

Leadership

  • Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer
  • Michael S. Weiss, Executive Vice Chairman, Strategic Development
  • David Jin, Chief Financial Officer and Head of Corporate Development
  • George Avgerinos, Ph.D., Senior Vice President, Biologics Operations
  • Samuel Berry, General Counsel and Corporate Secretary
  • Jimmie Harvey, Jr., M.D., Director
  • Malcolm Hoenlein, Director
  • Dov Klein, Director
  • J. Jay Lobell, Director
  • Kevin L. Lorenz, J.D., Director
  • Lucy Lu, M.D., Director

Last updated: 2024-12-31

Forte Biosciences, Inc.

Forte Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

FB-102

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Dallas, Texas, developing the FB-102 program for autoimmune diseases like vitiligo and alopecia areata.

Tags: FB-102, alopecia areata, autoimmune diseases, biopharmaceutical, vitiligo

Symbol: FBRX

Recent Price: $21.14

Industry: Biotechnology

CEO: Dr. Paul A. Wagner Ph.D.

Sector: Healthcare

Employees: 11

Address: 3060 Pegasus Park Drive, Dallas, TX 75247

Phone: 310 618 6994

Last updated: 2024-12-31

FibroGen, Inc.

FibroGen, Inc. logo
Market Cap: Lowest
Employees: Medium

Roxadustat, Pamrevlumab

Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.

Tags: anemia, antibody, biopharmaceutical, cancer, kidney disease, pulmonary fibrosis, therapeutics

Symbol: FGEN

Recent Price: $0.53

Industry: Biotechnology

CEO: Mr. Thane Wettig

Sector: Healthcare

Employees: 486

Address: 409 Illinois Street, San Francisco, CA 94158

Phone: 415 978 1200

Last updated: 2024-12-31

Onconetix, Inc.

Onconetix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Entadfi

Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing transformative therapies to address global health challenges. The company’s products include Entadfi for benign prostatic hyperplasia and various innovative vaccine candidates.

Tags: Entadfi, biotechnology, healthcare, pharmaceutical, therapies, vaccines

Symbol: ONCO

Recent Price: $0.44

Industry: Biotechnology

CEO: Dr. Ralph Schiess Ph.D.

Sector: Healthcare

Employees: 12

Address: 201 East Fifth Street, Cincinnati, OH 45202

Phone: 513 620 4101

Last updated: 2024-12-31

Sana Biotechnology, Inc.

Sana Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

N/A

Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines, developing cell engineering platforms for various therapeutic areas including oncology, diabetes, and genetic disorders.

Tags: biotechnology, cell engineering, genetic disorders, medicine, oncology

Symbol: SANA

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Steven D. Harr M.D.

Sector: Healthcare

Employees: 328

Address: 188 East Blaine Street, Seattle, WA 98102

Phone: 206 701 7914

Last updated: 2024-12-31

Cassava Sciences, Inc.

Cassava Sciences, Inc. logo
Market Cap: High
Employees: Lowest

simufilam

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead product candidate, simufilam, is a small molecule drug, recently completed Phase 2b clinical trial. The company also develops Sava Dx, a diagnostic to detect Alzheimer's disease.

Tags: Alzheimer's, Sava Dx, biotechnology, drug development, neurodegenerative diseases, simufilam

Symbol: SAVA

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Richard Jon Barry

Sector: Healthcare

Employees: 29

Address: 7801 North Capital of Texas Highway, Austin, TX 78731

Phone: 512 501 2444

Last updated: 2024-12-31

Sagimet Biosciences Inc.

Sagimet Biosciences Inc. logo
Market Cap: Low
Employees: Lowest

Denifanstat

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics called fatty acid synthase (FASN) inhibitors for diseases caused by dysfunctional lipid metabolism pathways. Its lead drug candidate, Denifanstat, targets nonalcoholic steatohepatitis and acne. The company is also working on FASN inhibitors for cancer treatment.

Tags: Denifanstat, FASN inhibitors, acne, biopharmaceutical, cancer, nonalcoholic steatohepatitis

Symbol: SGMT

Recent Price: $4.72

Industry: Biotechnology

CEO: Mr. David A. Happel

Sector: Healthcare

Employees: 8

Address: 155 Bovet Road, San Mateo, CA 94402

Phone: 650-561-8600

Leadership

  • George Kemble, PhD, Executive Chairman of the Board
  • David Happel, Chief Executive Officer
  • Anne Phillips, MD,
  • Beth Seidenberg, MD,
  • Elizabeth Grammer, Esq,
  • Jennifer Jarrett,
  • Merdad Parsey, MD, PhD,
  • Paul Hoelscher,
  • Tim Walbert,

Last updated: 2024-12-31

Synlogic, Inc.

Synlogic, Inc. logo
Market Cap: Lowest
Employees: Lowest

Synthetic Biotic Medicines

Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.

Tags: biopharmaceutical, drug development, immunological diseases, metabolic diseases, synthetic biotic

Symbol: SYBX

Recent Price: $1.40

Industry: Biotechnology

CEO: Mr. Antoine Awad

Sector: Healthcare

Employees: 6

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 401 9975

Last updated: 2024-12-31

Annovis Bio, Inc.

Annovis Bio, Inc. logo
Market Cap: Low
Employees: Lowest

Buntanetap

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound, Buntanetap, is in clinical trials for various neurodegenerative disorders.

Tags: Alzheimer's disease, Parkinson's disease, clinical trials, drug development, neurodegeneration

Symbol: ANVS

Recent Price: $5.08

Industry: Biotechnology

CEO: Dr. Maria L. Maccecchini Ph.D.

Sector: Healthcare

Employees: 6

Address: 1055 Westlakes Drive, Berwyn, PA 19312

Phone: 610 727 3913

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. logo
Market Cap: Highest
Employees: Medium

DEFINITY, Techne Lite, Xenon-133, Neurolite, Cardiolite, Thallium-201, Gallium-67, AZEDRA, Automated Bone Scan Index, Cobalt (Co 57), RELISTOR

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Tags: cardiovascular, diagnostic products, healthcare, oncology, radiotherapy, therapeutic products

Symbol: LNTH

Recent Price: $89.13

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Brian A. Markison

Sector: Healthcare

Employees: 834

Address: 331 Treble Cove Road, North Billerica, MA 01862

Phone: 978 671 8001

Leadership

  • Brian Markison, Chief Executive Officer
  • Paul Blanchfield, President
  • Jeff Humphrey, MD, Chief Medical Officer
  • Robert J. Marshall Jr., Chief Financial Officer
  • Amanda Morgan, Chief Commercial Officer
  • Daniel Niedzwiecki, Chief Administrative Officer, General Counsel and Corporate Secretary
  • Jean-Claude Provost, MD, Chief Science Officer
  • Jamie Spaeth, Chief People Officer
  • Cheryl Ball, Senior Vice President, Strategy and Enterprise Planning
  • Dorothy Barr, Senior Vice President, Manufacturing and Technical Operations
  • Kim Brown, Chief Accounting Officer
  • Lee Anne Howe, Chief Information Officer
  • Linda Lennox, Chief of Staff & Vice President, Corporate Communications
  • Joann Nestor, Senior Vice President, Legal Affairs
  • Andrea Sabens, Vice President, Business Optimization
  • Carol Walker, Senior Vice President, Quality
  • Mary Anne Heino, Chairperson of the Board
  • Minnie Baylor-Henry, Director
  • Gérard Ber, PhD, Director
  • Julie Eastland, Director
  • Samuel Leno, Director
  • Heinz Mäusli, Director
  • Julie McHugh, Director
  • Gary J. Pruden, Director
  • James H. Thrall, MD, Director

Last updated: 2024-12-31